The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "interstitial lung disease"

Search results for: interstitial lung disease

Exploring Leflunomide’s Role in RA with Interstitial Lung Disease

September 11, 2020 • By Rajandeep Paik, MD, FACR

Interstitial lung disease (ILD) is a hetero­geneous group of lung paren­chymal disorders that share several clinical, radiologic and histopathologic features, and are therefore grouped together.1 ILD can occur in association with most rheumatic connective tissue diseases (CTDs), but patients with systemic sclerosis, polymyositis, dermatomyositis and rheumatoid arthritis have the highest risk of developing ILD.2 A… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: interstitial lung disease (ILD), leflunomide

Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

October 18, 2019 • By Jason Liebowitz, MD

MADRID—Rheumatoid arthritis (RA) is among the most common autoimmune diseases in the U.S., affecting approximately 1.3 million U.S. adults.1 Although tremendous treatment advances have been made in recent years, one extra-articular manifestation of RA that continues to pose a challenge with regard to detection and management is interstitial lung disease (ILD). At the 2019 European… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: 2019 EULAR Congress, Interstitial Lung Disease

Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease

October 7, 2019 • By Reuters Staff

NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to… [Read More]

Filed Under: Conditions Tagged With: biopsy, Interstitial Lung Disease, lung, transbronchial lung cryobiopsy (TBLC)

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

October 2, 2019 • By Reuters Staff

NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in… [Read More]

Filed Under: Drug Updates Tagged With: ILD, Interstitial Lung Disease, lung disease, lungs, nintedanib

Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

July 1, 2019 • By Lara C. Pullen, PhD

A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…... [Read More]

Filed Under: Conditions

Recent Study Evaluates Nuclear Imaging in Interstitial Lung Disease

May 18, 2019 • By Larry Beresford

A recent proof-of-concept study to evaluate nuclear imaging in interstitial lung disease (ILD) concludes it is feasible to study ILD subtypes using this technology to visualize specific molecular processes of ILD. The process has important potential applications for the development of targeted molecular therapies.1 ILD is an umbrella term for a group of heterogeneous lung… [Read More]

Filed Under: Conditions Tagged With: computed tomography, Interstitial Lung Disease, Precision Medicine, SPECT

Interstitial Lung Disease: What Rheumatologists Need to Know

May 18, 2019 • By Gretchen Henkel

In the past decade, the treat-to-target concept has gained broad acceptance. Both the ACR and European League Against Rheumatism (EULAR) management recommendations include adding biologic therapies to the treatment regimen for rheumatoid arthritis (RA) patients who do not sufficiently respond to methotrexate monotherapy. “What EULAR says is that if [metho­trexate use fails], you should essentially… [Read More]

Filed Under: Conditions Tagged With: Interstitial Lung Disease

MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease

December 10, 2018 • By Lara C. Pullen, PhD

New research has linked the risk of developing interstitial lung disease in rheumatoid arthritis patients with the promoter variant in MUC5B, which may also contribute to the development of idiopathic pulmonary fibrosis and an unsual interstitial pneumonia seen by high-resolution CT scan…... [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: ILD, Interstitial Lung Disease, MUC5B, Rheumatoid Arthritis (RA)

Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease

April 9, 2018 • By Lara C. Pullen, PhD

A recent systematic review found no clear evidence that rheumatoid arthritis patients treated with cyclophosphamide have better lung function than those treated with mycophenolate mofetil. The researchers caution that physicians should expect treatment with cyclophosphamide may only result in a modest improvement in the preservation of forced vital capacity…... [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: cyclophosphamide, Interstitial Lung Disease, lung, lung disease, lungs, respiratory

CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease

December 18, 2017 • By Larry Beresford

A recent prospective, observational cohort study of potential clinical biomarkers for progression to interstitial lung disease (ILD) in patients with early systemic sclerosis (SSc) found that higher levels of CCL2 circulating in their plasma predicted both faster ILD progression and poorer survival rates than in those with lower levels.1 CCL2, also known as monocyte chemo­attractant… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: ACR Journal Review, American College of Rheumatology, Biomarker, chemokine, Clinical, cytokine, early systemic sclerosis, forced vital capacity, ILD, Interstitial Lung Disease, lung function, outcome, patient care, Research, Rheumatic Disease, rheumatology, study

  • 1
  • 2
  • 3
  • …
  • 17
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.